Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

The numerous beneficial health outcomes associated with the use of metformin to treat
patients with type 2 diabetes (T2DM), together with data from pre-clinical studies in animals …

Cardiovascular mortality is a major cause of death among in type 2 diabetes (T2DM).
Endothelial dysfunction (ED) is a well-known important risk factor for the development of …

Patients with diabetes type 2 have an increased risk for cardiovascular disease and
commonly use combination therapy consisting of the anti-diabetic drug metformin and a …

Metformin can suppress gluconeogenesis and reduce blood sugar by activating adenosine
monophosphate-activated protein kinase (AMPK) and inducing small heterodimer partner …

Since epidemiologic data have highlighted the positive effects of metformin to reduce cancer
incidence and mortality, many in vitro and in vivo studies as well as a large number of …

Metformin has been in clinical use for the management of type 2 diabetes for more than 60
years and is supported by a vast database of clinical experience: this includes evidence for …

Objective In population-based studies performed on multiple continents during the past two
decades, diabetes mellitus has been negatively associated with the prevalence and …

SARS-CoV-2 started spreading toward the end of 2019 causing COVID-19, a disease that
reached pandemic proportions among the human population within months. The reasons for …

Type 2 diabetes mellitus is one of the most common chronic disease worldwide and affects
all cross-sections of the society including children, women, youth and adults. Scientific …